SCHEMBL24258852

SCHEMBL24258852

COc1ncc(COCCCO)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.34
TUBB1 Q9H4B7 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33
TUBA1A Q71U36 1/20 0.33
TUBA1C Q9BQE3 1/20 0.33
TUBB6 Q9BUF5 1/20 0.33
TUBB2B Q9BVA1 1/20 0.33
ALKBH5 Q6P6C2 1/20 0.31
TNKS2 Q9H2K2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258970 0.80 TNKS2 (0.39) FTOL3MBTL1TNKS2HRH3
SCHEMBL28617813 0.78 TNKS2 (0.44) FTOTUBB1TUBB4ATUBBTUBA3C
SCHEMBL11196321 0.77 KDM4E (0.33) FTOTUBB1TUBB4ATUBBTUBA3C
SCHEMBL24258838 0.75 TUBB4A (0.35) FTOTUBB1TUBB4ATUBBTUBA3C
SCHEMBL29038049 0.74 TUBB4A (0.38) FTOTUBB1TDP1TUBB4ATUBB
SCHEMBL9904988 0.73 TUBB4A (0.40) FTOTUBB1TUBB4ATUBBTUBA3C
SCHEMBL4483666 0.71 L3MBTL1 (0.59) TDP1L3MBTL1NPC1POLBRAB9A
SCHEMBL11314244 0.71 LTA4H (0.41) TDP1L3MBTL1HRH3POLB
SCHEMBL21791399 0.71 FTO (0.38) FTOTUBB1TUBB4ATUBBTUBA3C
SCHEMBL29285378 0.69 L3MBTL1 (0.56) TDP1L3MBTL1NPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-05-05 US disclosed
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS FXR1, NR1H4, FXR2 FTO 4313/4885TUBB1 1387/4885TDP1 3982/4885
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 FTO 4313/4885TUBB1 1387/4885TDP1 3982/4885
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 FTO 4313/4885TUBB1 1387/4885TDP1 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.